Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas.

Press Release - ADVENTRX Pharmaceuticals, Inc. (ANX-NYSE Amex)

“ADVENTRX stands out among its small cap peers because we expect to submit an NDA, the final regulatory hurdle to drug approval, this year. There is only a limited amount of work remaining before we submit that NDA, and we have both the financial and human capital to get there.” - Brian M. Culley, M.A., M.B.A. (ANX) (Interview published June 18, 2010)

The Most Powerful Name In Corporate News and Information.

CURRENT ISSUE  |  COVER ARCHIVES  |   INDEX   |  CONTACT  |  FINANCIALS  |  MARKETING SERVICES   |   HOME PAGE


CEOCFO-
Members Login
Become A Member!



 
ADVENTRX Pharmaceuticals to Present at the OneMedForum Business Development and Investment Conference on June 23
SAN DIEGO, June 16, 2011 /PRNewswire via COMTEX/ --

ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the OneMedForum Business Development and Investment Conference on Thursday June 23rd, 2011, at 10:30am Eastern time, in the Plaza Room at the Roosevelt Hotel in New York.

Interested parties can access a live audio webcast and slide presentation on the ADVENTRX Pharmaceuticals web site at www.adventrx.com. An archived presentation will be available on the web site for 30 days.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company focused on acquiring, developing and commercializing proprietary product candidates. Two of the Company's lead product candidates, Exelbine(TM), or ANX-530 (vinorelbine injectable emulsion) and ANX-514 (docetaxel emulsion for injection), are novel emulsion formulations of currently marketed chemotherapy drugs. The Company's other lead product candidate, ANX-188, is a novel, purified, rheologic and antithrombotic compound, which initially is being developed as a first-in-class treatment for pediatric patients with sickle cell disease in acute crisis. More information can be found on the Company's web site at www.adventrx.com.

SOURCE ADVENTRX Pharmaceuticals, Inc.

. 




    

ceocfointerviews.com does not purchase or make
recommendation on stocks based on the interviews published.